Listing is a "key leap" on the way of enterprise development. As Yingpai Pharmaceuticals opens a new chapter in its development.The number of listed biomedical companies in the new zone has increased to 10The city's pharmaceutical companies, almost half of the city's "listed army".
What is it about these companies that earns them the attention of capital?
Jiangbei, and why can frequently run out of listed companies?
01Each company, each with its own specialty
The spotlight of the capital market always shines for "hard power".
Turning to the list of listed pharmaceutical companies in the north of the river, this logic line is equally clear:Each business, practicing on its own track of the"Jedi".
Yingpai Pharmaceuticals, which has just been listed on the gong, holds a technological bottom card.
This "card" is one that can beNew anti-cancer therapy with "precise identification and targeted elimination"., which can selectively kill cancer cells and reduce the impact on normal tissues.
How tough is this "card"? The anti-cancer drug Paishuning® launched by Yingpai Pharmaceutical is one of the only three PARP1/2 inhibitors approved for the first-line maintenance treatment of ovarian cancer for the whole population in China, and has been included in the medical insurance. The team's two innovative drugs under research have been spotted by overseas companies, and the team has won a global license agreement with a total transaction value of nearly 1 billion US dollars.
With "a card", knocking on the door of the capital market. As the city's first company to land on the Science and Technology Innovation Board, Nanwei Medical also used a "small clip" to pry the global market.
The company's star product "Harmony Clip", not only breaks through the traditional hemostatic clip operation difficult pain points, but also the price of imported products to 1/8, by many doctors around the world called "the world's best clip".Sells nearly 10 million pieces a year, generating hundreds of millions of dollars in revenue. Today, Nanwei Medical's products cover over 6,000 hospitals nationwide and its business extends to more than 90 countries and regions. The data shows thatEvery minute, on average, the world has58 patients are usingthey areany productThe
When you maximize your niche, you always have a story to tell:
Last year's Hong Kong-listed VeliChiBo, whose core product, LBL-024, is a 4-1BB target on theWorld's First Drug Candidate to Enter Registered Clinical Stage.;
Pharmachem Bio has establishedThe world's largest repository of genetically engineered miceThe company has nearly 30,000 genetically engineered mouse models in hand, and has created the "industry myth" of going public within five years of its founding;
Jianyou, which landed on the SSE earlier, wasOne of the world's largest suppliers of heparin APIsHeparin Preparations Sold Overseas ......
Capital is willing to real money "bet" quality enterprises and breakthroughs in innovation, and in Jiangbei, there are always "strengths" running on each track.
02 Beyond the Jedi, there's ecology
Enterprises break in on their own meritsIPO, but a number of companies frequently "run out", alsoA city can't do that without a sustained and deepThe ecological build.
In this ecology.Industry thicknessIt is the most critical "home base".
Among the 10 listed companies, 8 of them are from the Biomedical Valley of the New District, and Longwang Mountain has witnessed every stage of their growth. Why can we gather such a group of "seed players"? Pharmaceutical Valley Park since its inception, early targeting gene cell therapy and other cutting-edge track to attract projects, build up strength, when more than 1,300 companies landed, industrial clusters are becoming more and more plentiful, naturally stepping into the "harvest period".
In this ecology.Professional and patientIt's the deeper undertones.
Yingpai Pharmaceuticals listed in the cornerstone lineup, Tencent, Eli Lilly Asia Fund and other head capital in addition to the state-owned capital of Jiangbei New Area in the list. Every round of financing during the critical period of development of VILI Zhibo has been supported by the investment of the new zone. The new district also established an innovativetotal sizeA $1 billion offshore listed industrial investment fundIn addition, the company focuses on investing in enterprises in the new zone that are going to be listed in Hong Kong and other overseas markets, and it is with the support of this "real money" that PharmaJet Ankang has taken a key step forward.
In this ecology, there is also a need forGraded Incubation SystemThere is the "Lark Program", which is specifically designed for high-growth SMEs. There is a special "Spirit Sparrow Program" for high-growth science and technology-based small and medium-sized enterprises, which can provide start-up teams with start-up capital and talent support; when the team grows and develops, and the new technology is transferred to production, the "Bones Growing Flesh Program" will promote the expansion of high-quality enterprises to increase their capital and production; Even if you are only one person, the OPC community here is also open to empower every dream. ......
There is soil, sunshine and rain, it is such a powerful ecosystem that makes the road under the feet of enterprises, more and more smooth and clear.
03 Looking forward to more "nexts"
At this writing, both of the opening questions have been answered - theEnterprises based on technology, relying on the product to speak; the new area to ecological support, with the escort service, which has led to one good news story after another.
Of course, the corporate rush to IPOs continues.
Yingshi biological, Zhengxiang pharmaceutical, Norin biological ...... since the second half of last year, the new area, there are a number of enterprises "relay" to Hong Kong to submit the form. Among them, there is no lack of the best in their respective tracks to lead the race:
The two original drugs of Yingshi Biologicals have attracted industry leader Fosun Pharmaceuticals to spend a huge amount of money to introduce, with an authorized value of more than 1 billion yuan; Zhenxiang Pharmaceuticals independently researched and developed a new anti-influenza drug Jikexu, which was approved for listing in July last year and has been on-line on the Jingdong health platform, and has become a "regular home supply" for many people... ...many innovative achievements, but alsoThe question of "Who is the next listed company?The
Who's next? Depends on the speed of the respective sprints. We certainly look forward toThe "next one" will be listed as soon as possible, but what is more important than the "next one" is that each of them has its own irreplaceable track, and there is still a steady stream of "the next one".
The gong has just been set for Imperium Pharmaceuticals, but Jiangbei has long been ready for the next gong. About the future, we look forward together.
